You are here

Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer.

Title: Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer.
15 views
3 downloads
Name(s): Hoyne, Gerard, author
Rudnicka, Caroline, author
Sang, Qing-Xiang, author
Roycik, Mark, author
Howarth, Sarah, author
Leedman, Peter, author
Schlaich, Markus, author
Candy, Patrick, author
Matthews, Vance, author
Type of Resource: text
Genre: Journal Article
Text
Date Issued: 2016-02-24
Physical Form: computer
online resource
Extent: 1 online resource
Language(s): English
Abstract/Description: Prostate cancer is the second most frequently diagnosed cancer in men worldwide. Current treatments include surgery, androgen ablation and radiation. Introduction of more targeted therapies in prostate cancer, based on a detailed knowledge of the signalling pathways, aims to reduce side effects, leading to better clinical outcomes for the patient. ADAM19 (A Disintegrin And Metalloproteinase 19) is a transmembrane and soluble protein which can regulate cell phenotype through cell adhesion and proteolysis. ADAM19 has been positively associated with numerous diseases, but has not been shown to be a tumor suppressor in the pathogenesis of any human cancers. Our group sought to investigate the role of ADAM19 in human prostate cancer. ADAM19 mRNA and protein levels were assessed in well characterised human prostate cancer cohorts. ADAM19 expression was assessed in normal prostate epithelial cells (RWPE-1) and prostate cancer cells (LNCaP, PC3) using western blotting and immunocytochemistry. Proliferation assays were conducted in LNCaP cells in which ADAM19 was over-expressed. In vitro scratch assays were performed in PC3 cells over-expressing ADAM19. Immunohistochemical studies highlighted that ADAM19 protein levels were elevated in normal prostate tissue compared to prostate cancer biopsies. Results from the clinical cohorts demonstrated that high levels of ADAM19 in microarrays are positively associated with lower stage (p = 0.02591) and reduced relapse (p = 0.00277) of human prostate cancer. In vitro, ADAM19 expression was higher in RWPE-1 cells compared to LNCaP cells. In addition, human ADAM19 over-expression reduced LNCaP cell proliferation and PC3 cell migration. Taken together, our immunohistochemical and microarray results and cellular studies have shown for the first time that ADAM19 is a protective factor for human prostate cancer. Further, this study suggests that upregulation of ADAM19 expression could be of therapeutic potential in human prostate cancer.
Identifier: FSU_pmch_26912236 (IID), 10.1186/s12885-016-2178-4 (DOI), PMC4766641 (PMCID), 26912236 (RID), 26912236 (EID), 10.1186/s12885-016-2178-4 (PII)
Publication Note: This NIH-funded author manuscript originally appeared in PubMed Central at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766641.
Subject(s): ADAM Proteins/genetics
ADAM Proteins/metabolism
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Cell Line, Tumor
Cell Movement
Cell Proliferation
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Male
Middle Aged
Neoplasm Grading
Neoplasm Recurrence, Local
Neoplasm Staging
Prognosis
Prostatic Neoplasms/genetics
Prostatic Neoplasms/metabolism
Prostatic Neoplasms/mortality
Prostatic Neoplasms/pathology
Tumor Necrosis Factor-alpha/metabolism
Persistent Link to This Record: http://purl.flvc.org/fsu/fd/FSU_pmch_26912236
Host Institution: FSU
Is Part Of: BMC cancer.
1471-2407
Issue: vol. 16

Choose the citation style.
Hoyne, G., Rudnicka, C., Sang, Q. -X., Roycik, M., Howarth, S., Leedman, P., … Matthews, V. (2016). Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer. Bmc Cancer. Retrieved from http://purl.flvc.org/fsu/fd/FSU_pmch_26912236